Get the Stockscreener App
118.95
0.80%
0.94
After Hours:
118.95
Guardant Health Inc stock is traded at $118.95, with a volume of 2.72M.
It is up +0.80% in the last 24 hours and up +32.82% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$118.01
Open:
$119.06
24h Volume:
2.72M
Relative Volume:
1.29
Market Cap:
$15.77B
Revenue:
$1.08B
Net Income/Loss:
$-433.19M
P/E Ratio:
-34.98
EPS:
-3.4004
Net Cash Flow:
$-225.09M
1W Performance:
+25.32%
1M Performance:
+32.82%
6M Performance:
+12.83%
1Y Performance:
+221.05%
1-Day Range:
$116.81
$120.15
1-Week Range:
$93.29
$121.01
52-Week Range:
$36.36
$121.01
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
118.95 | 15.65B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health, Inc. (GH) Stock Analysis: 48.3% Revenue Growth Fuels Investor Optimism - DirectorsTalk Interviews
Guardant gets FDA nod for next-gen cancer mutation blood test - Mugglehead Investment Magazine
Guardant wins FDA nod for Guardant360 Liquid CDx cancer test - MSN
A Look At Guardant Health’s Valuation After Its Recent Share Price Surge - Yahoo Finance
Guardant Health (GH) Is Up 25.3% After FDA Clears First Genomic‑Epigenomic Liquid Biopsy Panel – Has The Bull Case Changed? - Yahoo Finance
Guardant Health Stock 5-Day Winning Spree: Stock Climbs 25% - Trefis
Guardant Health Stock On Fire: Up 25% With 5-Day Winning Streak - Trefis
Insider Sell: John Saia Sells 20,000 Shares of Guardant Health I - GuruFocus
Guardant Health director Ian T. Clark disposes of $735k in shares - Investing.com UK
Guardant Health chief legal officer sells $2.13m in stock - Investing.com UK
Guardant Health director Ian T. Clark disposes of $735k in shares By Investing.com - Investing.com South Africa
Guardant Health chief legal officer sells $2.13m in stock By Investing.com - Investing.com Australia
Guardant Health insider cashless exercise reported (NASDAQ: GH) - Stock Titan
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health Insider Sold Shares Worth $23,076,690, According to a Recent SEC Filing - Moomoo
Guardant Health Insider Sold Shares Worth $2,130,229, According to a Recent SEC Filing - Moomoo
Guardant Health (GH) Chief Legal Officer sells 20,000 shares in open-market trades - Stock Titan
Guardant Health (GH) co-CEO’s family trust sells 210K shares of stock - Stock Titan
Family trust of Guardant Health (NASDAQ: GH) director sells 6,876 shares in open market - Stock Titan
Guardant Health (NASDAQ: GH) director sells 1,250 shares after exercising options - Stock Titan
Guardant Health stock gains on early FDA approval for G360 test By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 120.74 USD By Investing.com - Investing.com Nigeria
Research Alert: CFRA Maintains Buy Rating On Shares Of Guardant Health - Moomoo
Guardant Health stock hits 52-week high at 120.74 USD - Investing.com
Guardant Health stock gains on early FDA approval for G360 test - Investing.com Australia
Guardant wins FDA approval for updated liquid biopsy - MedTech Dive
NORTH SQUARE DYNAMIC SMALL CAP FUND's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health leaps on a major win in cancer detection; will shares break out? - MSN
Guardant Health (GH) Shares Rise Following FDA Approval of Guard - GuruFocus
Why Guardant Health (GH) Is Up 16.8% After Hiking 2026 Revenue Guidance on Shield Momentum - simplywall.st
Guardant Health (GH) Gains FDA Approval for New Liquid Biopsy Te - GuruFocus
Guardant Health secures FDA approval for expanded liquid biopsy test - MSN
Guardant Health (GH) Form 144 lists brokered proposed sales and restricted stock lapses - Stock Titan
Guardant Health (NASDAQ: GH) affiliate sale notice; 1,300 shares sold previously - Stock Titan
Guardant Health Stock Climbs As Q1 Beat Fuels Bullish Targets - StocksToTrade
Guardant Health receives FDA approval for expanded liquid biopsy test By Investing.com - Investing.com Australia
Guardant Health Stock Climbs As Growth Story Accelerates - timothysykes.com
Guardant Health Stock Rallies After Shield-Fueled Earnings Beat - StocksToTrade
Why is Guardant Health stock surging today? By Investing.com - Investing.com Australia
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy TestGuardant Health (NASDAQ:GH) - Benzinga
FDA approval advances personalized cancer diagnostics - BioWorld News
Guardant Health Stock Jumps 10% to $108 on Momentum From Record Q1 Revenue Beat and Raised Guidance - International Business Times Australia
Guardant Health Stock Builds Momentum After Q1 Beat And Analyst Upgrades - timothysykes.com
Guardant Health Receives FDA Approval for New Cancer Test - Intellectia AI
Quinn Emanuel Gets $3 Million Sanction in Drug Advertising Case - Bloomberg Law News
Guardant wins FDA nod for Guardant360 Liquid CDx (GH:NASDAQ) - Seeking Alpha
Guardant Health Receives FDA Approval for New Liquid Biopsy - Intellectia AI
Guardant Health receives FDA approval for expanded liquid biopsy test - Investing.com
Guardant Health Says US FDA Approved Liquid Biopsy Test - Moomoo
Fda approves new Guardant360 liquid cdx, the largest FDA-approved liquid biopsy panel with a 100x expanded footprint - marketscreener.com
New cancer blood test gains FDA approval with 100x wider gene view - Stock Titan
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):